Investor Centre
We are a leading, clinical-stage stem cell business. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.
93.5p
0.000p
at 21-07-2018 8:07:01
15 minute delayed share price from London Stock Exchange provided by Euroland.
